+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Somatostatin Analogs Market - Global Forecast 2026-2032- Product Image
Somatostatin Analogs Market - Global Forecast 2026-2032- Product Image
New

Somatostatin Analogs Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 191 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5337116
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The somatostatin analogs market stands at an inflection point, shaped by rapid advances in formulation and integration into diverse care models. As clinical needs broaden and regulatory developments shift, senior decision-makers require an actionable perspective to guide market strategy and ensure operational resilience.

Market Snapshot: Growth Trajectory of the Somatostatin Analogs Market

The somatostatin analogs market is set on a strong upward trajectory, having expanded from USD 8.30 billion in 2025 to USD 9.19 billion in 2026. With an expected CAGR of 10.60%, the market is projected to achieve USD 16.81 billion by 2032. Key growth drivers include rising demand for advanced formulations, broader clinical adoption across disease states, and increasingly dynamic global access frameworks. Companies are investing in novel delivery platforms and improving patient access strategies, while heightened competition is refining value propositions for both healthcare providers and payers.

Scope & Segmentation: Somatostatin Analogs Market Landscape

This report delivers senior-level clarity into the makeup and complexity of the somatostatin analogs market, equipping leaders with insights across operational and clinical segments:

  • Molecule Types: Encompasses lanreotide, octreotide, and pasireotide, which vary in receptor affinity, dosing intervals, and positioning in therapeutic regimens.
  • Clinical Indications: Targets acromegaly, Cushing’s disease, and neuroendocrine tumors, each presenting unique patient pathways, management needs, and resource requirements.
  • Administration Routes: Covers both intramuscular and subcutaneous injection, influencing care setting decisions, training protocols, and patient-centric approaches.
  • End Users: Involves clinics, home care services, and hospitals, each representing distinct procurement patterns, reimbursement models, and access points for patients.
  • Distribution Channels: Includes hospital, retail, and online pharmacies, each impacting dispensing efficiencies, patient outreach, and engagement dynamics.
  • Dosage Forms: Focuses on cartridges alongside prefilled syringes, affecting usability, cold chain logistics, and compatibility with administration technologies.
  • Regions Covered: Americas, Europe, Middle East & Africa, and Asia-Pacific, enabling nuanced analysis of market entry challenges and local adoption drivers.
  • Innovative Technologies: Identifies the integration of peptide engineering, digital health tools, real-world evidence platforms, and sophisticated delivery devices that elevate patient monitoring and care outcomes.

Key Takeaways for Senior Decision-Makers

  • Emerging advancements in stability, delivery modes, and safety support the growing use of somatostatin analogs in both endocrine and oncology care pathways.
  • Market stakeholders must now demonstrate economic value and enhanced patient outcomes, aligning evidence generation with payer and provider expectations.
  • Strategic collaboration with device manufacturers and digital health innovators is facilitating a shift to at-home treatment settings, boosting patient adherence and enabling stronger real-world evidence collection.
  • Regional differences in reimbursement approaches, regulatory requirements, and provider network maturity are central to tailoring market access and product positioning strategies.
  • Custom segmentation by molecule, indication, and delivery approach supports precise clinical development and alignment with shifting payer needs across geographies.
  • Proactive supply chain and scenario planning are required to maintain agility as global trade policies and regulatory landscapes evolve.

Tariff Impact: Navigating U.S. Policy Shifts

The upcoming 2025 United States tariff changes are prompting manufacturers to localize production and develop dual-sourcing partnerships, boosting supply chain resilience and containing costs. Procurement teams are updating tender processes, while compliance functions monitor customs and documentation to minimize risk. These shifts drive transparency for provider contracts and help sustain patient access regardless of import allocation shifts.

Methodology & Data Sources

This report synthesizes peer-reviewed clinical literature, regulatory filings, clinical trial databases, and de-identified real-world data to create a comprehensive analysis. Qualitative interviews with clinical and supply chain experts add market context. Scenario mapping and region-by-region regulatory review underpin all recommendations.

Somatostatin Analogs Market: Why This Report Matters

  • Supports investment planning and resource allocation by illustrating how innovation, flexible commercial models, and regulatory agility combine to unlock opportunities.
  • Allows supply chain and procurement leaders to anticipate tariff-driven impacts, optimize supplier choices, and plan for uninterrupted delivery.
  • Enables clinical development and frontline commercial teams to use deep segmentation, real-world practice insights, and evolving stakeholder priorities to fine-tune market approaches.

Conclusion

The somatostatin analogs market is characterized by ongoing clinical and operational transformation. Leaders who align strategy with shifts in care delivery, regulatory frameworks, and access models will be best positioned to drive sustainable success.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Somatostatin Analogs Market, by Molecule Type
8.1. Lanreotide
8.2. Octreotide
8.3. Pasireotide
9. Somatostatin Analogs Market, by Route Of Administration
9.1. Intramuscular Injection
9.2. Subcutaneous Injection
10. Somatostatin Analogs Market, by Dosage Form
10.1. Cartridges
10.2. Prefilled Syringes
11. Somatostatin Analogs Market, by Application
11.1. Acromegaly
11.2. Cushing's Disease
11.3. Neuroendocrine Tumors
12. Somatostatin Analogs Market, by End User
12.1. Clinics
12.2. Home Care Services
12.3. Hospitals
13. Somatostatin Analogs Market, by Distribution Channel
13.1. Hospital Pharmacies
13.2. Online Pharmacies
13.3. Retail Pharmacies
14. Somatostatin Analogs Market, by Region
14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific
15. Somatostatin Analogs Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Somatostatin Analogs Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. United States Somatostatin Analogs Market
18. China Somatostatin Analogs Market
19. Competitive Landscape
19.1. Market Concentration Analysis, 2025
19.1.1. Concentration Ratio (CR)
19.1.2. Herfindahl Hirschman Index (HHI)
19.2. Recent Developments & Impact Analysis, 2025
19.3. Product Portfolio Analysis, 2025
19.4. Benchmarking Analysis, 2025
19.5. Aurobindo Pharma Limited
19.6. Camurus AB
19.7. Cipla Limited
19.8. Dr. Reddy's Laboratories Ltd.
19.9. Fresenius SE & Co. KGaA
19.10. Glenmark Pharmaceuticals Limited
19.11. Hikma Pharmaceuticals PLC
19.12. Ipsen S.A.
19.13. Lupin Limited
19.14. Mylan N.V.
19.15. Novartis AG
19.16. Pfizer Inc.
19.17. Recordati Industria Chimica e Farmaceutica S.p.A.
19.18. Sun Pharmaceutical Industries Ltd.
19.19. Teva Pharmaceutical Industries Ltd.
19.20. Zydus Lifesciences Limited
List of Figures
FIGURE 1. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL SOMATOSTATIN ANALOGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL SOMATOSTATIN ANALOGS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 14. CHINA SOMATOSTATIN ANALOGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY LANREOTIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY LANREOTIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY LANREOTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY OCTREOTIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY OCTREOTIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY OCTREOTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY PASIREOTIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY PASIREOTIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY PASIREOTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY CARTRIDGES, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY CARTRIDGES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY CARTRIDGES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY PREFILLED SYRINGES, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY PREFILLED SYRINGES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY PREFILLED SYRINGES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY ACROMEGALY, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY ACROMEGALY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY ACROMEGALY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY CUSHING'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY CUSHING'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY CUSHING'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY HOME CARE SERVICES, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY HOME CARE SERVICES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY HOME CARE SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 58. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 59. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 60. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 61. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 62. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 63. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 64. NORTH AMERICA SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. NORTH AMERICA SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 66. NORTH AMERICA SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 67. NORTH AMERICA SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 68. NORTH AMERICA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 69. NORTH AMERICA SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 70. NORTH AMERICA SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 71. LATIN AMERICA SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. LATIN AMERICA SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 73. LATIN AMERICA SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 74. LATIN AMERICA SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 75. LATIN AMERICA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 76. LATIN AMERICA SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 77. LATIN AMERICA SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 85. EUROPE SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. EUROPE SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 87. EUROPE SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 88. EUROPE SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 89. EUROPE SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 90. EUROPE SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 91. EUROPE SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 92. MIDDLE EAST SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. MIDDLE EAST SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 94. MIDDLE EAST SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 95. MIDDLE EAST SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 96. MIDDLE EAST SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 97. MIDDLE EAST SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 98. MIDDLE EAST SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 99. AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 100. AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 101. AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 102. AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 103. AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 104. AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 105. AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 106. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 107. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 108. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 109. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 110. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 111. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 112. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 114. ASEAN SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. ASEAN SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 116. ASEAN SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 117. ASEAN SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 118. ASEAN SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 119. ASEAN SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 120. ASEAN SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 121. GCC SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 122. GCC SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 123. GCC SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 124. GCC SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 125. GCC SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 126. GCC SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 127. GCC SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 128. EUROPEAN UNION SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 129. EUROPEAN UNION SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 130. EUROPEAN UNION SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 131. EUROPEAN UNION SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 132. EUROPEAN UNION SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 133. EUROPEAN UNION SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 134. EUROPEAN UNION SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 135. BRICS SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 136. BRICS SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 137. BRICS SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 138. BRICS SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 139. BRICS SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 140. BRICS SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 141. BRICS SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 142. G7 SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 143. G7 SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 144. G7 SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 145. G7 SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 146. G7 SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 147. G7 SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 148. G7 SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 149. NATO SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 150. NATO SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 151. NATO SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 152. NATO SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 153. NATO SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 154. NATO SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 155. NATO SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 156. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 157. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 158. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 159. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 160. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 161. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 162. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 163. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 164. CHINA SOMATOSTATIN ANALOGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 165. CHINA SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 166. CHINA SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 167. CHINA SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 168. CHINA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 169. CHINA SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 170. CHINA SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Somatostatin Analogs market report include:
  • Aurobindo Pharma Limited
  • Camurus AB
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Fresenius SE & Co. KGaA
  • Glenmark Pharmaceuticals Limited
  • Hikma Pharmaceuticals PLC
  • Ipsen S.A.
  • Lupin Limited
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • Recordati Industria Chimica e Farmaceutica S.p.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages191
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 9.19 Billion
Forecasted Market Value ( USD ) by 2032 $ 16.81 Billion
Compound Annual Growth Rate10.6%
Regions CoveredGlobal
No. of Companies Mentioned17

Related Topics

Related Reports

Somatostatin Analogs Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Somatostatin Analogs Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Somatostatin Analogs Market Report 2025 - Product Image

Somatostatin Analogs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Somatostatin Analogs - Global Strategic Business Report - Product Image

Somatostatin Analogs - Global Strategic Business Report

  • Report
  • 280 Pages
  • Global
From
Somatostatin Analogs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Somatostatin Analogs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 180 Pages
  • Global
From
Somatostatin Analogs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Somatostatin Analogs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 130 Pages
  • Global
From

About the Somatostatin Analogs Market

Somatostatin Analogs are a class of drugs used in the treatment of oncology. They are used to inhibit the release of hormones, such as growth hormone, which can be overproduced in certain types of cancer. Somatostatin Analogs are used to treat a variety of cancers, including neuroendocrine tumors, carcinoid tumors, and pancreatic islet cell tumors. They are also used to treat acromegaly, a condition caused by excessive growth hormone production. Somatostatin Analogs are administered either intravenously or subcutaneously, depending on the type of cancer being treated. The Somatostatin Analogs market is a rapidly growing segment of the oncology drugs market. It is driven by the increasing prevalence of cancer, as well as the development of new and improved drugs. The market is expected to continue to grow in the coming years, as more drugs are developed and approved for use. Some of the major companies in the Somatostatin Analogs market include Novartis, Pfizer, Merck, and Sanofi. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.